

IN THE CLAIMS

1-14 (canceled)

15 (currently amended) A method for the treatment of infections by Herpesviridae and/or skin tumors in a subject comprising administering to the ~~to the~~ subject an active amount of at least 0.1 mg and higher of xenogeneic oligo- and/or polyribonucleotides per unit dose once per recurrence.

16-18 (cancel)

19. (currently amended) A method for treating lesions of the skin and/or mucosa caused by ~~herpes-simplex~~ Herpes simplex virus and/or ~~varicella-zoster~~ Varicella zoster virus comprising administering a therapeutically effective amount of the pharmaceutical composition comprising xenogenic oligo- and/or polyribonucleotides of claim 25 to a subject in need thereof once per recurrence.

20. (currently amended) A method for the treatment of infections by Herpesviridae and/or skin tumors, comprising administering an active amount of at least 0.1 mg and higher of xenogeneic oligo- and/or polyribonucleotides in an anhydrous preparation per dose unit is administered once per recurrence to the subject. ~~subject.~~

21. (new) A method for the treatment of infections by at least one of Herpesviridae or skin tumors comprising administering to a subject in need thereof a therapeutically effective amount of xenophic oligo- and/or polyribonucleotides.

22. (new) The method of claim 21, wherein the therapeutically effective amount of at least 0.1 mg.

23. (new) The method of claim 15, wherein said oligo- and/or polyribonucleotides are administered topically.
24. The method of claim 23, wherein said oligo- and/or polyribonucleotides are a powder.
25. (new) The method of claim 19, wherein said oligo- and/or polyribonucleotides are administered topically.
26. (new) The method of claim 25, wherein said oligo- and/or polyribonucleotides are a powder.
27. (new) The method of claim 20, wherein said oligo- and/or polyribonucleotides are administered topically.
28. (new) The method of claim 27, wherein said oligo- and/or polyribonucleotides are a powder.
29. (new) The method of claim 15, wherein said xenogenic oligo-and/or polyribonucleotides are obtained directly from a plant, an animal or a unicellular organism.
30. (new) The method of claim 19, wherein said xenogenic oligo-and/or polyribonucleotides are obtained directly from a plant, an animal or a unicellular organism.
31. (new) The method of claim 20, wherein said xenogenic oligo-and/or polyribonucleotides are obtained directly from a plant, an animal or a unicellular organism.
32. (new) The method of claim 29, wherein said oligo- and/or polyribonucleotides are administered topically.
33. (new) The method of claim 29, wherein said oligo- and/or polyribonucleotides are a powder.
34. (new) The method of claim 30, wherein said oligo- and/or polyribonucleotides are administered topically.

35. (new) The method of claim 30, wherein said oligo- and/or polyribonucleotides are a powder.
36. (new) The method of claim 31, wherein said oligo- and/or polyribonucleotides are administered topically.
37. (new) The method of claim 31, wherein said oligo- and/or polyribonucleotides are a powder.